Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
ConditionLung Cancer Stage IA
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorShanghai Chest Hospital
About this trial
The aim of this study is to investigate the efficacy and safety of transthoracic versus transbronchial ablation in the treatment of early stage peripheral lung cancer.
Eligibility criteria
Qualifiers
Age greater than 18 years.
Primary peripheral lung cancer diagnosed by pathology and pre-procedure staging examination suggesting clinical stage T1N0M0, stage IA (including postoperative new and multiple primary).
The proposed ablation lesion was evaluated for feasibility of CT and bronchoscopy-guided ablation treatment.
Consent to initial ablation therapy is given after assessment of unsuitability for surgery or refusal of surgery and signed informed consent form.
Disqualifiers
Patients with platelets <50×109/L, severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term.
Patients with severe pulmonary fibrosis and pulmonary arterial hypertension.
Infectious and radioactive inflammation around the lesion, skin infection at the puncture site that is not well controlled, systemic infection, high fever >38.5°C.
Patients with severe hepatic, renal, cardiac, pulmonary and cerebral insufficiency, severe anaemia, dehydration and serious disorders of nutritional metabolism that cannot be corrected or improved in the short term.
Trial design
Treatments tested in this trial
- ablation
Treatment groups
110 Participants
are divided into 2 treatment groupsSponsors and collaborators
Shanghai Chest Hospital
Lead sponsor
Sir Run Run Shaw Hospital
Collaborator
Beijing Chao Yang Hospital
Collaborator
Source ClinicalTrials.gov